Nanoliposomal Irinotecan (Nal-IRI, ONIVYDE®) in Combination With TAS-102 (LONSURF®) in Refractory Solid Tumors

Refractory Solid Tumors Clinical Trial

Official title:

Phase 1 Study of Nanoliposomal Irinotecan (Nal-IRI, ONIVYDE®) in Combination With TAS-102 (LONSURF®) in Refractory Solid Tumors

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03810742
• Other study ID #: PEP0210
• Status: Completed
• Phase: Phase 1
• Start date: March 5, 2019
• Est. completion date: October 25, 2023

Study information

• Verified date: November 2023
• Source: PharmaEngine
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study is to explore the combination of nal-IRI and TAS-102, which is expected to be an effective regimen that could be applied to various cancers

Description:

Primary Objectives

• to determine the maximum tolerated dose (MTD) of nal-IRI (ONIVYDE®) in combination with TAS-102 (LONSURF®)

• to evaluate the toxicity profile of the combination therapy Secondary Objectives

• to evaluate the preliminary efficacy of the combination therapy of nal-IRI (ONIVYDE®) and TAS-102 (LONSURF®)

• to study the pharmacokinetics of the combination therapy

A phase 1 study with a classical 3 + 3 dose escalation design. The target population is patients who have pathologically confirmed malignant solid tumors with no standard treatment available.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 44
• Est. completion date: October 25, 2023
• Est. primary completion date: May 4, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Ages between 20 to 70 years old

2. Histologically or cytologically confirmed malignant solid tumors which are advanced or metastatic, have failed standard treatment or have no standard treatment currently available

3. ECOG performance status 0 or 1

4. Normal ECG or ECG without any clinically significant findings

5. Adequate hematologic parameters, and hepatic and renal function i. White blood cell (WBC) count 3000/µL and absolute neutrophil count (ANC) 1500/µL ii. Platelet counts 100,000/µL without platelet transfusion within 14 days iii. Hemoglobin level 10 g/dL iv. Serum total bilirubin- within normal range v. Serum albumin 3.0 g/dL vi. Serum alanine aminotransferase (ALT) 3 x the upper limit of normal (ULN) vii. Serum creatinine 1.5 x ULN

Exclusion Criteria:

1. Received prior nal-IRI (ONIVYDE®) or TAS-102 (LONSURF®) therapy

2. Known hypersensitivity to any of the components of nal-IRI, other liposomal products, fluoropyrimidines or leucovorin

3. Have liver cirrhosis with Child-Pugh B or Child-Pugh C

4. With active CNS metastasis (indicated by clinical symptoms, cerebral edema, steroid requirement, or progressive growth)

5. With clinically significant gastrointestinal disorder including hepatic disorders, bleeding, inflammation, occlusion, or diarrhea > grade 1

6. Life expectancy of less than 3 months

7. Use any anti-cancer or investigational product within 14 days prior to the first date of study dosing

8. History of any second malignancy in the latest 5 years except curatively treated non-melanoma skin cancer or treated cervical carcinoma in situ

9. Uncontrolled inter-current illness including, but not limited to, ongoing or active infection requiring antibiotic treatment, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia, and psychiatric illness or social situation that would preclude study compliance

10. Homozygous for the UGT1A1 28 allele (TA7/TA7), homozygous for UGT1A1 6 allele (A/A), or double heterozygous for both UGT1A1 28 allele (TA6/TA7) and UGT1A1 6 allele (G/A) (only for dose-finding phase)

11. Pregnant or breastfeeding women

Related Conditions & MeSH terms

• Neoplasms
• Refractory Solid Tumors

Intervention

Drug:
• Nanoliposomal Irinotecan
Nanoliposomal Irinotecan (nal-IRI, ONIVYDE®) in Combination with TAS-102 (LONSURF®)

Locations

Country	Name	City	State
Taiwan	China Medical University Hospital	Taichung
Taiwan	National Cheng Kung University Hospital	Tainan

Sponsors (1)

Lead Sponsor	Collaborator
PharmaEngine

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Determination of Dose Limiting Toxicities (DLT)	to find the Dose Limiting Toxicity (DLT) of nal-IRI (ONIVYDE®) in combination with TAS-102 (LONSURF®)	12 months
Primary	Evaluation of Safety profile of nal-IRI and TAS-102 - Incidence of Treatment-Emergent Adverse Events	Incidence of Treatment-Emergent Adverse Events [Safety] of nal-IRI (ONIVYDE®) in combination with TAS-102 (LONSURF®) according to NCI-CTCAE version 5.0	12 months
Secondary	Evaluation of objective tumor response as per Response Evaluation Criteria in Solid Tumors (RECIST)	the objective tumor rate by using RECIST v1.1	24 months
Secondary	Pharmacokinetics study - (Cmax)	Concentration of Peak Plasma (Cmax)	6 months
Secondary	Pharmacokinetics study - (Tmax)	maximum concentration of the time taken to reach the (Tmax).	6 months
Secondary	Pharmacokinetics study - (T1/2)	time of C max to drop in half taken (T1/2)	6 months
Secondary	Pharmacokinetics study - (AUC0?t)	area of the plasma concentration versus time curve (AUC0?t).	6 months
Secondary	Pharmacokinetics study - (AUC0?8)	area of the plasma concentration versus under curve (AUC0?8)	6 months
Secondary	Pharmacokinetics study - (CL)	rate of clearance (CL)	6 months